卡培他滨和替莫唑胺治疗小肠（中肠）神经内分泌肿瘤的疗效。
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
机构信息
Department of GI Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Department of Diagnostic Imaging, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
出版信息
Curr Oncol. 2022 Jan 26;29(2):510-515. doi: 10.3390/curroncol29020046.
The capecitabine/temozolomide regimen has significant activity in pancreatic NETs; however, data are limited in NETs of the small bowel (midgut). A retrospective study of all patients with metastatic midgut NETs seen at Moffitt Cancer Center between January 2008 and June 2019 treated with CAPTEM was conducted. 32 patients with proven or suspected well-differentiated primary small bowel NETs (excluding duodenum) were identified. 6 patients were found to have a radiographic response (19%), 5 of whom had high-grade disease. Only one patient among 23 with low/intermediate-grade disease responded (4%), whereas the response rate for patients with high-grade disease was 56%. Among patients with low/intermediate-grade disease, 44% discontinued due to poor tolerability. The CAPTEM regimen appears to have an activity in patients with high-grade small bowel NETs and is largely inactive in patients with low/intermediate-grade tumors.
卡培他滨/替莫唑胺方案在胰腺神经内分泌肿瘤（NET）中具有显著的活性；然而，在小肠（中肠）NET 中的数据有限。对 2008 年 1 月至 2019 年 6 月期间在 Moffitt 癌症中心就诊的所有转移性中肠 NET 患者进行了一项回顾性研究，这些患者均接受 CAPTEM 治疗。确定了 32 例经证实或疑似分化良好的原发性小肠 NET（不包括十二指肠）患者。发现 6 例患者有影像学反应（19%），其中 5 例为高级别疾病。在 23 例低/中级别疾病患者中，只有 1 例（4%）有反应，而高级别疾病患者的反应率为 56%。在低/中级别疾病患者中，由于不耐受，44%的患者停止治疗。CAPTEM 方案似乎对高级别小肠 NET 患者具有活性，而对低/中级别肿瘤患者则基本无效。
Zotero 插件